BridgeBio sales of new heart drug outstrip expectations
In its first full quarter, Attruby made more headway than analysts anticipated in its competition with Pfizer’s market-leading drug.
In its first full quarter, Attruby made more headway than analysts anticipated in its competition with Pfizer’s market-leading drug.
![[Podcast] Behind the Breakthroughs: How Almac Powers Clinical Trial Success with Care](https://imgproxy.divecdn.com/5lAJkli_KcGt1FSsw4EaegjgP76IHREqYEWbhNBJOXw/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9CaW9QaGFybWFEaXZlXzEzNDZfeF83MjlfQXJ0d29yay5qcGc=.webp)
